Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients (ONTARGET-INDIA)
A Non-Interventional, Multicentre, Prospective, Observational Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Patients. (ONTARGET-India)
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This is a multicentre, non-interventional, prospective, observational study which would be conducted in India to understand the usage and effect of saxagliptin as first add-on therapy after metformin. The study will enroll Type 2 Diabetes Mellitus (T2DM) patients who were inadequately controlled with metformin alone and have been recently (i.e. within past 15 days) prescribed saxagliptin as an add-on to metformin.
The Investigator/designee would get signed informed consent from potential subjects of the study. The patients who meet all inclusion and none of the exclusion criteria will be enrolled in the study. These patients will then be assigned a patient identification number for the study. The Investigator/designee will collect the information as per the study schedule. This will be considered as Visit 1 of the patients. The patients will be managed as per the routine clinical practice of the physician for their condition and this study will neither interfere/advise the Investigators/designee for any drug/medication to be prescribed to the patients nor prescribe any intervention to them.The enrolled patients would then be asked to visit their respective study sites after 3 months ( +7 days) for the Visit-2 of study.
Around 50 study centers throughout India will be selected with a goal of enrolling up to 1500 patients (approximately 30 subjects each per site). The study will be initiated after obtaining written approval of Independent/Institutional Ethics Committee and written Informed consent of the patient.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
new Delhi, Indien
- Research Site
-
-
Andhra Pradesh
-
Nellure, Andhra Pradesh, Indien
- Research Site
-
Vishakhapatnam, Andhra Pradesh, Indien
- Research Site
-
-
Assam
-
Guwahati, Assam, Indien
- Research Site
-
-
Delhi
-
New Delhi, Delhi, Indien
- Research Site
-
-
Gujarat
-
Ahmedabad, Gujarat, Indien
- Research Site
-
Rajkot, Gujarat, Indien
- Research Site
-
Vadodara, Gujarat, Indien
- Research Site
-
-
Haryana
-
Karnal, Haryana, Indien
- Research Site
-
Yamunanagar, Haryana, Indien
- Research Site
-
-
Karnataka
-
Bangalore, Karnataka, Indien
- Research Site
-
-
Kerala
-
Trivandrum, Kerala, Indien
- Research Site
-
-
Kochi
-
Cochin, Kochi, Indien
- Research Site
-
-
Madhya Pradesh
-
Bhopal, Madhya Pradesh, Indien
- Research Site
-
Indore, Madhya Pradesh, Indien
- Research Site
-
-
Maharashtra
-
Mumbai, Maharashtra, Indien
- Research Site
-
Pune, Maharashtra, Indien
- Research Site
-
-
Punjab
-
Amritsar, Punjab, Indien
- Research Site
-
Chandigarh, Punjab, Indien
- Research Site
-
Ludhiana, Punjab, Indien
- Research Site
-
-
Rajasthan
-
Jaipur, Rajasthan, Indien
- Research Site
-
Udaipur, Rajasthan, Indien
- Research Site
-
-
Tamiladu
-
Madurai, Tamiladu, Indien
- Research Site
-
-
Tamilnadu
-
Chennai, Tamilnadu, Indien
- Research Site
-
-
Telangana
-
Hyderabad, Telangana, Indien
- Research Site
-
Hyderebad, Telangana, Indien
- Research Site
-
-
Uttar Pradesh
-
Allahabad, Uttar Pradesh, Indien
- Research Site
-
Kanpur, Uttar Pradesh, Indien
- Research Site
-
Lucknow, Uttar Pradesh, Indien
- Research Site
-
Noida, Uttar Pradesh, Indien
- Research Site
-
-
West Bengal
-
Kolkata, West Bengal, Indien
- Research Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Patients willing to provide informed consent.
- Female or male patients aged 18 years or above.
- Patients with known case of Type 2 diabetes mellitus.
- Patients with inadequate glycaemic control taking metformin monotherapy (minimum dose of 500 mg OD) for at least 3 months.
- Patients who have recently (last 15 days) been prescribed saxagliptin in addition to metformin.
Exclusion Criteria:
- Patients with Type 1 diabetes mellitus.
- Patients taking glucose lowering drugs apart from metformin or saxagliptin.
- Any medical condition of the patient which in the opinion of Investigator would interfere with safe completion of the study.
- Pregnant or lactating women.
- Women of childbearing potential not ready to use an effective barrier contraceptive method during the study.
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Medication usage in enrolled subjects
Tidsram: at 3 months
|
By Frequency of subjects taking different doses of saxagliptin and metformin
|
at 3 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Reduction in HbA1C
Tidsram: baseline and at 3 months
|
Compare the reduction in HbA1C levels from baseline to follow up visit with baseline HbA1C levels
|
baseline and at 3 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Dr Sanjay Kalra, MD, DM (Endocrinology), Bharti Research Institute of Diabetes & Endocrinology, Karnal
- Studierektor: Dr Bhavesh P Kotak, FRCS, MS, D Orth, AstraZeneca Pharma India Ltd
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- D1680R00019
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .